Dolby Family Ventures

AI research assistant for biology.

Montara Therapeutics is a biotechnology company that focuses on developing a precision pharmacology platform aimed at creating innovative therapies for central nervous system diseases. By leveraging human genetics and machine learning, the company identifies and validates drug targets, which enhances the ability of medical professionals to deliver safe and effective treatments for patients suffering from neurological disorders. Montara Therapeutics' approach is designed to improve therapeutic outcomes and address unmet medical needs in the field of neurology.

Esper Satellite Imagery is a company focused on developing a constellation of hyperspectral imaging satellites equipped with in-house built imagers that cover over 100 spectral bands with a ground sampling distance of 1 meter. The company specializes in creating modular satellites capable of capturing detailed hyperspectral imagery to enhance agricultural practices and optimize mining operations. Their technology allows for precise measurements of various environmental factors, including water quality and plant health, which are essential for sustainable farming. Additionally, the satellites facilitate the identification of underground ore deposits, contributing to more efficient mining processes. Esper Satellite Imagery's capabilities also extend to monitoring the impacts of climate change, providing valuable environmental data to clients, and promoting resource efficiency for future generations.

NeuroBionics is a biotechnology firm focused on advancing precision bioelectronic medicine through the development of innovative implanted devices. The company specializes in creating a new class of electronic medicine designed to revolutionize neuromodulation techniques. By developing flexible neuroprostheses that can bi-directionally interface with soft organs, NeuroBionics aims to modulate organ function, treat various diseases, and enhance patient quality of life. Through its cutting-edge technology, the firm seeks to empower healthcare providers to address the specific needs of their patients effectively.

Calicat is a clean-energy company developing a proprietary electrocatalyst discovery process for electrolyser. The company electrocatalyst discovery is an unprecedented, proprietary, end-to-end ultrahigh throughput AI and data-driven process focused on the discovery of new catalysts for the generation of clean hydrogen and fuel cell power production. The process prepares, characterizes, and quantifies the catalytic activity of millions of compositions per month and then closes the loop with big data analysis and AI to refine/guide the search.

Vandria is a biotechnology company focused on developing mitophagy inducers aimed at rejuvenating cells to combat aging and chronic diseases. By targeting the autophagy process, Vandria's products facilitate the elimination and recycling of damaged mitochondria, which is essential for maintaining proper mitochondrial function. This innovative approach seeks to help patients mitigate the effects of age-related disorders and improve overall health. Through its research and development efforts, Vandria aims to provide effective solutions for individuals facing the challenges associated with aging and chronic health conditions.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

Montara Therapeutics is a biotechnology company that focuses on developing a precision pharmacology platform aimed at creating innovative therapies for central nervous system diseases. By leveraging human genetics and machine learning, the company identifies and validates drug targets, which enhances the ability of medical professionals to deliver safe and effective treatments for patients suffering from neurological disorders. Montara Therapeutics' approach is designed to improve therapeutic outcomes and address unmet medical needs in the field of neurology.

Progentos Therapeutics is a biopharmaceutical company focused on developing innovative therapies for chronic diseases, specifically targeting multiple sclerosis. The company has created novel small-molecule therapeutics aimed at activating oligodendrocyte progenitor cells, which play a crucial role in myelin regeneration. By stimulating the body's natural repair mechanisms, Progentos Therapeutics seeks to help patients recover lost functions and enhance their quality of life. Through its research and development efforts, the company is committed to addressing the unmet medical needs of those affected by multiple sclerosis.

Esper Satellite Imagery is a company focused on developing a constellation of hyperspectral imaging satellites equipped with in-house built imagers that cover over 100 spectral bands with a ground sampling distance of 1 meter. The company specializes in creating modular satellites capable of capturing detailed hyperspectral imagery to enhance agricultural practices and optimize mining operations. Their technology allows for precise measurements of various environmental factors, including water quality and plant health, which are essential for sustainable farming. Additionally, the satellites facilitate the identification of underground ore deposits, contributing to more efficient mining processes. Esper Satellite Imagery's capabilities also extend to monitoring the impacts of climate change, providing valuable environmental data to clients, and promoting resource efficiency for future generations.

LeoLabs Inc., established in 2015 and based in Menlo Park, California, specializes in providing high-resolution data on objects in low Earth orbit through its phased-array radars. The company offers foundational mapping data and services, including rapid orbit determination, early operational support, and ongoing conjunction awareness, to mitigate collision risks for commercial satellite operators, government agencies, and satellite management services. Its innovative platform, LeoLabs Collision Avoidance, automates and modernizes satellite operations, serving as a basis for new generations of space situational awareness (SSA) and traffic safety services.

Motif Neurotech is a company focused on developing minimally invasive bioelectronic implants aimed at monitoring and treating severe mental illnesses, particularly treatment-resistant depression. Through its innovative approach, the company specializes in wireless power and data transmission, which facilitates the creation of new, miniature implants designed for tissue stimulation and diagnostic readings. This technology enables patients to potentially repair neural circuits using minimally invasive electronic therapies, offering hope for more effective treatment options for those struggling with mental health challenges.

Cognitive Space is a company that specializes in developing an artificial intelligence platform aimed at enhancing satellite constellation management. By leveraging machine intelligence, the platform facilitates mission management, collections planning, and communications link coordination for satellite operators. This innovative technology enables organizations to optimize their satellite capacity in response to dynamic market demands, thereby unlocking significant revenue and operational potential. Cognitive Space's solutions contribute to more effective monitoring of Earth, supporting economic, environmental, and national security initiatives within the rapidly evolving space industry.

Mojo Vision Inc. is a technology company based in Saratoga, California, founded in 2015. The company specializes in the development of augmented reality solutions, focusing on high-performance micro-LED display technology. Mojo Vision has created the world's smallest and densest dynamic display for smart contact lenses, which are designed to provide users with timely information seamlessly and hands-free, without the distractions associated with traditional mobile devices. The company is also engaged in a joint development agreement with Menicon Co., Ltd. to explore smart contact lens products, further enhancing its innovative offerings. By combining advanced display and semiconductor expertise with proprietary quantum-dot technology, Mojo Vision aims to revolutionize the display industry, addressing diverse applications across consumer, enterprise, and government sectors.

Sharrow Marine is a subsidiary of Sharrow Engineering, specializing in the research and development of high-performance propulsion technologies for both maritime and aeronautical applications. The company designs energy-efficient propellers that are custom-engineered to enhance performance across various sectors, including commercial marine shipping, aerospace, and recreational boating. Sharrow Marine's innovative solutions cater to a wide range of uses, ensuring clients can achieve improved efficiency in their propulsion systems.

Paradromics, Inc. is a company focused on developing advanced brain-machine interfaces aimed at transmitting data between the brain and external devices. Founded in 2015 and based in Austin, Texas, Paradromics manufactures implantable systems that facilitate neural data decoding, converting intricate neural recordings into data streams suitable for various neural prostheses. The company's technology is designed to enhance data transmission rates, providing high-volume, bidirectional data streaming capabilities. This innovation aims to assist individuals with neurodegenerative diseases and other neurological conditions by compensating for the loss of biological connectivity. In addition to its core products, Paradromics also develops applications to support its technology solutions.

Genemod Corporation, based in Seattle, Washington, develops a unified inventory management platform specifically designed for life scientists. Founded in 2018, the company offers a suite of tools that includes project management software, sequence editing capabilities, and an intuitive dashboard for laboratory operations. Genemod's proprietary technology integrates both scientific and administrative functionalities, facilitating real-time communication, scheduling, and knowledge sharing among researchers. The platform effectively manages laboratory inventory, including consumables, reagents, and equipment, while employing artificial intelligence to enhance data analysis, report generation, and experimental design. This user-centered and scalable solution aims to improve efficiency, collaboration, and productivity in research environments.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages groundbreaking research from the Akassoglou lab at Gladstone/UCSF, which identifies fibrin as a crucial factor in driving chronic innate immune activation associated with various diseases. By creating therapeutics that address neuroinflammation and vascular dysfunction, Therini Bio aims to provide potential treatments for conditions such as multiple sclerosis, thereby enhancing the quality of life for patients facing these challenging health issues.

Mojo Vision Inc. is a technology company based in Saratoga, California, founded in 2015. The company specializes in the development of augmented reality solutions, focusing on high-performance micro-LED display technology. Mojo Vision has created the world's smallest and densest dynamic display for smart contact lenses, which are designed to provide users with timely information seamlessly and hands-free, without the distractions associated with traditional mobile devices. The company is also engaged in a joint development agreement with Menicon Co., Ltd. to explore smart contact lens products, further enhancing its innovative offerings. By combining advanced display and semiconductor expertise with proprietary quantum-dot technology, Mojo Vision aims to revolutionize the display industry, addressing diverse applications across consumer, enterprise, and government sectors.

MooveAI is an automotive company that provides innovative solutions in end-to-end, predictive road intelligence analytics. Their first approach involves continuously collecting trillions of data points about road networks, including data about connected vehicles, road attributes, such as friction and traffic. The data is then integrated into our proprietary location analytics platform, where it is verified and analyzed. Finally, actionable insights are provided in the form of road risk scores that describe the relative safety of millions of individual road segments.

Switch Therapeutics is a biotechnology company founded in 2020 and based in San Francisco, California. The company focuses on revolutionizing RNA interference (RNAi) therapies by developing biomarker-gated genetic medicines. These innovative therapies utilize nucleic acid nanotechnology and RNAi science to target a variety of diseases, particularly those affecting the central nervous system and other systemic conditions with significant unmet medical needs. Switch Therapeutics aims to provide healthcare providers with RNA molecules and therapies that can be activated selectively in specific cells, enhancing the precision of treatments for central nervous system diseases.

AccuKnox is a developer of a zero-trust runtime security platform designed for cloud-native organizations. The company offers a comprehensive cloud security solution that protects infrastructure and applications throughout the software development lifecycle. Its platform utilizes a differentiated DevSecOps and open-source approach to secure various environments, including public and private clouds, Kubernetes, virtual machines, bare metal, IoT Edge, and 5G security. By isolating and safeguarding all types of container workloads with identity as a perimeter, AccuKnox enables clients to effectively monitor and control tainted data, networking, and system-level restrictions, ensuring robust protection for applications, networks, and sensitive data.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Founded in 2016 and headquartered in Boston, Massachusetts, with a branch in Cambridge, United Kingdom, Cerevance utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, within mature human brain tissue. By leveraging a substantial repository of over 15,000 human brain samples, the company generates extensive expression and epigenetic data, guiding the identification of promising therapeutic targets. This approach aims to address the early onset of central nervous system diseases by revealing critical transcriptional and epigenetic differences within affected brain regions.

Authentic Vision GmbH is a company specializing in anti-counterfeiting and authentication technologies aimed at safeguarding investments in product innovation, brand value, and reputation. Founded in 2012 and headquartered in Salzburg, Austria, with an additional office in Saratoga, California, the company offers a unique solution that includes a patented label technology combining QR code features with holographic security aspects. Its flagship product, the CheckifReal application, allows users to visually distinguish between authentic and counterfeit labels. Additionally, Authentic Vision provides services for customer communication, client label management, and business intelligence. The company holds multiple patents and collaborates closely with universities and leading security printing firms to remain at the forefront of advancements in brand protection and consumer engagement solutions.

Atomos Space is an aerospace company developing orbital transfer vehicles and space propulsion technologies, including space nuclear options, to enable flexible and cost-efficient access to space. The company's systems are designed to provide maneuverability and a sustainable orbital environment, allowing satellite operators to reach diverse orbits and destinations without relying on heavy, costly propulsion. By simplifying access to space and reducing propulsion burdens, Atomos Space seeks to lower operating costs and expand the range of viable mission profiles for payloads in orbit.

Cajal Neuroscience is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. It employs a combination of human genetics, functional genomics, and advanced microscopy techniques to identify novel targets and therapeutics. The company utilizes viral tools and platforms for screening targets that influence the progression of neurodegenerative conditions, alongside functional genetic screening and multi-omics methods. By integrating these state-of-the-art approaches, Cajal Neuroscience aims to advance precision medicine, ultimately enabling healthcare professionals to improve treatment outcomes for patients suffering from neurodegenerative disorders.

MedCrypt Inc. is a cybersecurity company specializing in the protection of medical devices. Founded in 2016 and based in Encinitas, California, MedCrypt provides data security solutions for a wide range of medical devices, including implantable devices like pacemakers and various surgical robots. The company's platform offers data security as a service to medical device original equipment manufacturers (OEMs), enabling them to implement essential security features quickly and efficiently. These features include user authentication, data encryption, and transaction monitoring to detect potential malicious behavior. By integrating security capabilities into medical devices with minimal code, MedCrypt allows engineers to focus on developing innovative clinical functionalities while ensuring the safety and integrity of device operations.

Canaery is developing a neural interface that analyzes an object's scent fingerprint to identify dangerous compounds at ports and inspection points, potentially replacing or supplementing x-ray and camera methods. The company aims to digitize the sense of scent through a neurotech device that interprets scents entering an olfactory system and prioritizes those relevant to customers, enabling the identification of hazardous compounds and the underlying object or its state. By translating olfactory information into actionable signals, Canaery seeks to enhance security and inspection efficiency in high-risk environments.

OKAPI:Orbits provides an AI-powered space traffic management platform that predicts collision risks, manages conjunctions, and optimizes satellite operations to enable safer, more efficient use of crowded orbits. The platform includes environment visualization, maneuver design, conjunction analysis, re-entry predictions, high-accuracy orbit propagation and determination, and pass prediction, with secure ground-segment integration for space operators and institutions. The company aims to support sustainable space activity by reducing collision risk and enabling reliable operations in increasingly congested space.

Ubotica is a company focused on deploying advanced artificial intelligence technologies aboard satellites. It specializes in developing semi-autonomous satellite systems that deliver real-time insights from space directly to users. Ubotica offers technical expertise in computer vision and machine learning for embedded systems, catering to various market segments including space, Internet of Things, industry, and biomedical applications. By leveraging these technologies, Ubotica enables clients to optimize the performance and output of their satellite systems.

DigiLens Inc. is a technology company based in Sunnyvale, California, specializing in holographic waveguide display solutions for extended reality (XR) applications. Founded in 1997 and formerly known as SBG Labs, DigiLens has developed a patented optical platform and photopolymer technology that enables original equipment manufacturers (OEMs) to create customizable XR devices for various sectors, including automotive, enterprise, consumer, avionics, and military. The company offers a range of products, such as the Crystal30 and Crystal50 lenses, which facilitate the design of waveguide-based displays. Additionally, DigiLens provides innovative solutions like the DigiLens AutoHUD, which enhances the field of view of traditional heads-up displays, and CrystalClear, an augmented reality heads-up display. Supporting its offerings, DigiLens also supplies light engines and hardware development kits, such as Insight30, to assist users in developing wearable devices.

Diamond Age is a company focused on automating the home construction process within the production housing industry. By leveraging advanced technologies such as 3D printing, mechatronics, and robotics, Diamond Age aims to address significant labor shortages and enhance efficiency in construction. The company's Robotics-as-a-Service system streamlines the building process, reducing construction timelines from approximately nine months to just thirty days. Additionally, Diamond Age collaborates with landholders to simplify the supply chain, enabling more affordable housing options for home buyers. Through its innovative approach, the company seeks to unlock substantial growth potential in the housing market.

Mojo Vision Inc. is a technology company based in Saratoga, California, founded in 2015. The company specializes in the development of augmented reality solutions, focusing on high-performance micro-LED display technology. Mojo Vision has created the world's smallest and densest dynamic display for smart contact lenses, which are designed to provide users with timely information seamlessly and hands-free, without the distractions associated with traditional mobile devices. The company is also engaged in a joint development agreement with Menicon Co., Ltd. to explore smart contact lens products, further enhancing its innovative offerings. By combining advanced display and semiconductor expertise with proprietary quantum-dot technology, Mojo Vision aims to revolutionize the display industry, addressing diverse applications across consumer, enterprise, and government sectors.

MindImmune Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapeutic drugs that target the immune system to address diseases of the central nervous system. Incorporated in 2016 and headquartered in Kingston, Rhode Island, the company aims to treat conditions such as Alzheimer's disease, Huntington's disease, pain, and psychiatric disorders. MindImmune recognizes the critical interplay between the immune system and brain function, positioning itself at the forefront of research in this area. The company is also establishing collaborations with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to enhance its drug development efforts through access to academic resources within the expanding Rhode Island neuroscience ecosystem.

Ursa Major Technologies, Inc., established in 2015 and based in Berthoud, Colorado, specializes in manufacturing propulsion solutions tailored for the microsatellite and nanosatellite launch market. The company's product portfolio includes the Ursa Major Hadley and Ripley engines, which are predominantly (over 80%) additively manufactured using innovative, proprietary materials and processes. These engines, running on liquid oxygen and kerosene, are designed to provide superior performance, reliability, and cost-effectiveness for aerospace clients.

Sepion Technologies is an advanced membrane company based in Emeryville, California, founded in 2015. It specializes in the development of highly-tunable nanoscale membranes designed for various industrial applications, particularly in the energy storage sector. The company focuses on manufacturing innovative lithium-metal batteries by integrating nanoscience, polymer chemistry, and cell engineering. Its proprietary composite membrane serves as a cost-effective alternative to traditional ceramic separators used in lithium batteries, allowing for large-area production. This technology enables battery manufacturers to enhance energy density in their products, thereby improving overall performance and efficiency in energy storage solutions.

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. The company specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. Its flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on individualized peripheral nerve stimulation to enhance patient outcomes. In addition to its work on essential tremor, the company is also developing therapies for conditions such as Parkinson's disease, as well as exploring applications in psychiatry, cardiology, and autoimmune disorders.

DigiLens Inc. is a technology company based in Sunnyvale, California, specializing in holographic waveguide display solutions for extended reality (XR) applications. Founded in 1997 and formerly known as SBG Labs, DigiLens has developed a patented optical platform and photopolymer technology that enables original equipment manufacturers (OEMs) to create customizable XR devices for various sectors, including automotive, enterprise, consumer, avionics, and military. The company offers a range of products, such as the Crystal30 and Crystal50 lenses, which facilitate the design of waveguide-based displays. Additionally, DigiLens provides innovative solutions like the DigiLens AutoHUD, which enhances the field of view of traditional heads-up displays, and CrystalClear, an augmented reality heads-up display. Supporting its offerings, DigiLens also supplies light engines and hardware development kits, such as Insight30, to assist users in developing wearable devices.

TripleBlind operates an online platform that enables entities to collaborate on sensitive data and algorithms without compromising privacy. Founded in 2019 and headquartered in Kansas City, Missouri, the company provides a software-only solution delivered via a simple API. This solution focuses on healthcare and financial services, leveraging principles like federated learning and multi-party compute to enhance scalability and processing speed. TripleBlind supports major cloud platforms and ensures compliance with regulations such as HIPAA and GDPR, making it a robust tool for unlocking the intellectual property value of data while preserving privacy. The company is backed by notable investors including Accenture, General Catalyst, and The Mayo Clinic.

Calicat is a clean-energy company developing a proprietary electrocatalyst discovery process for electrolyser. The company electrocatalyst discovery is an unprecedented, proprietary, end-to-end ultrahigh throughput AI and data-driven process focused on the discovery of new catalysts for the generation of clean hydrogen and fuel cell power production. The process prepares, characterizes, and quantifies the catalytic activity of millions of compositions per month and then closes the loop with big data analysis and AI to refine/guide the search.

Acrigen Biosciences is focused on advancing gene editing technologies to enhance the safety and efficiency of CRISPR-Cas based systems. Founded in 2019 and headquartered in Berkeley, California, the company develops precision gene editing solutions aimed at producing effective and safe in vivo drug therapies for various diseases. Acrigen's innovations include Acro proteins that regulate the CRISPR-Cas gene editing process, along with a bioinformatics discovery software platform designed to identify suitable CRISPR systems for human therapeutic applications. By improving anti-CRISPR proteins and optimizing genetic therapies, Acrigen aims to contribute significantly to the field of medicine and the treatment of debilitating conditions.

Diamond Age is a company focused on automating the home construction process within the production housing industry. By leveraging advanced technologies such as 3D printing, mechatronics, and robotics, Diamond Age aims to address significant labor shortages and enhance efficiency in construction. The company's Robotics-as-a-Service system streamlines the building process, reducing construction timelines from approximately nine months to just thirty days. Additionally, Diamond Age collaborates with landholders to simplify the supply chain, enabling more affordable housing options for home buyers. Through its innovative approach, the company seeks to unlock substantial growth potential in the housing market.

Paradromics, Inc. is a company focused on developing advanced brain-machine interfaces aimed at transmitting data between the brain and external devices. Founded in 2015 and based in Austin, Texas, Paradromics manufactures implantable systems that facilitate neural data decoding, converting intricate neural recordings into data streams suitable for various neural prostheses. The company's technology is designed to enhance data transmission rates, providing high-volume, bidirectional data streaming capabilities. This innovation aims to assist individuals with neurodegenerative diseases and other neurological conditions by compensating for the loss of biological connectivity. In addition to its core products, Paradromics also develops applications to support its technology solutions.

Strateos specializes in automating chemistry, biology, and tissue analysis in closed-loop robotic labs, accelerating drug discovery programs for pharmaceutical partners. By combining advanced robotics, software for imaging and analytics, and remote cloud laboratories, Strateos enables more rapid and efficient discovery of new drug candidates. The company was formed through a merger of Transcriptic, which developed the first robotic cloud laboratory platform for life science research, and 3Scan, which specialized in automating tissue analysis. Strateos aims to express life science methods as data, enabling infrastructure virtualization and driving the next generation of discovery with significant time and cost efficiencies.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages groundbreaking research from the Akassoglou lab at Gladstone/UCSF, which identifies fibrin as a crucial factor in driving chronic innate immune activation associated with various diseases. By creating therapeutics that address neuroinflammation and vascular dysfunction, Therini Bio aims to provide potential treatments for conditions such as multiple sclerosis, thereby enhancing the quality of life for patients facing these challenging health issues.

TripleBlind operates an online platform that enables entities to collaborate on sensitive data and algorithms without compromising privacy. Founded in 2019 and headquartered in Kansas City, Missouri, the company provides a software-only solution delivered via a simple API. This solution focuses on healthcare and financial services, leveraging principles like federated learning and multi-party compute to enhance scalability and processing speed. TripleBlind supports major cloud platforms and ensures compliance with regulations such as HIPAA and GDPR, making it a robust tool for unlocking the intellectual property value of data while preserving privacy. The company is backed by notable investors including Accenture, General Catalyst, and The Mayo Clinic.

Roviero is an AI startup focused on developing advanced graph processors that enhance edge computing. The company has created proprietary technologies, including the CortiOne Neural Processing Engine and the CortiSoft compiler, which deliver exceptional performance with minimal power consumption and latency for edge devices. Roviero's Native Graph AI Processor stands out in the market by enabling native intelligence in various devices, such as cameras, IoT devices, mobile phones, and computers. This innovative processor not only offers industry-disruptive performance but also simplifies programming for product designers, facilitating the development of a new generation of intelligent edge-based devices. By reducing compiler complexity and optimizing power usage, Roviero aims to democratize AI computing, making it more accessible across multiple applications.

CytoVale, Inc. is a medical technology company based in San Francisco, California, that specializes in developing innovative biomarkers utilizing the mechanical properties of individual cells, a field known as mechanomics. Founded in 2013, the company employs microfluidics technology to effectively route and physically probe single cells, allowing for the simultaneous measurement of multiple biomarkers. This approach aims to enhance early detection and diagnosis of immune-mediated diseases, particularly sepsis. By leveraging cell mechanics and machine learning, CytoVale seeks to revolutionize the diagnostic landscape, ultimately improving patient outcomes and reducing treatment costs in healthcare.

Sea Machines Robotics, headquartered in Boston, Massachusetts, specializes in developing and manufacturing advanced autonomous control and navigation systems for the commercial marine industry. Established in 2014, the company produces systems like SM300 for remote vessel command, SM200 for collaborative operations, SM400 for AI-powered situational awareness on container ships, RC NXT for PLC-based wireless control, and DP-NXT for crew reduction or elimination on vessels. Sea Machines offers solutions for various unmanned applications, including bathymetric surveys, AUV-tendering, subsea asset inspection, passive acoustic monitoring, and dual towing.

Authentic Vision GmbH is a company specializing in anti-counterfeiting and authentication technologies aimed at safeguarding investments in product innovation, brand value, and reputation. Founded in 2012 and headquartered in Salzburg, Austria, with an additional office in Saratoga, California, the company offers a unique solution that includes a patented label technology combining QR code features with holographic security aspects. Its flagship product, the CheckifReal application, allows users to visually distinguish between authentic and counterfeit labels. Additionally, Authentic Vision provides services for customer communication, client label management, and business intelligence. The company holds multiple patents and collaborates closely with universities and leading security printing firms to remain at the forefront of advancements in brand protection and consumer engagement solutions.

Libra Therapeutics, Inc. is a biotechnology company based in San Diego, California, that specializes in developing novel disease-modifying therapeutics aimed at addressing neurodegenerative diseases. Founded in 2019, the company focuses on restoring cellular balance disrupted by these conditions. Its therapeutic platform utilizes distinct molecular approaches to enhance autophagy, allowing for the rapid clearance of toxic proteins and the reduction of neurotoxic protein production. Libra Therapeutics targets multiple neurodegenerative disorders, including amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease, with the intention of offering effective treatments that mitigate the impact of these debilitating ailments.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

NativeWaves is a technology company that specializes in audio synchronization and streaming solutions aimed at enhancing live event viewing experiences. By collaborating with partners, the company identifies compelling content and develops tools that allow for personalized and synchronized delivery of multimedia content across multiple screens. NativeWaves' software effectively translates movies, sports events, and videos into various languages without causing interruptions or synchronization delays. Additionally, it provides real-time statistics and insights on alternate screens, enabling viewers to engage with their favorite events in preferred languages and formats. The company's commitment to delivering intuitive and user-friendly technology ensures that existing workflows remain unchanged while enhancing the overall experience for audiences worldwide.

Atomwise, Inc. is a biotechnology company specializing in deep learning artificial intelligence technology for small molecule drug discovery. Based in San Francisco and founded in 2012, the company has developed AtomNet, a pioneering AI platform that facilitates virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical analysis of experimental affinity measurements and protein structures. Atomwise is focused on addressing over 600 unique disease targets and has established collaborations with over 250 partners, including prominent pharmaceutical and biotechnology firms. By leveraging its advanced technology, Atomwise aims to revolutionize the drug discovery process and advance a pipeline of small-molecule drug candidates into preclinical studies. The company was previously known as Chematria, Inc. and rebranded to Atomwise, Inc. in 2015.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis employs proprietary platforms and biomarkers to create precision medicines that target genetically validated disease-causing alterations. The company’s pipeline includes innovative treatments aimed at specific subtypes of ALS, such as therapies that restore dysfunctional cellular waste clearance, manage overactive neurons, and eliminate toxic proteins. Through its advanced antisense oligonucleotides and small molecule programs, QurAlis seeks to halt disease progression and significantly improve patient outcomes for those affected by ALS.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Founded in 2016 and headquartered in Boston, Massachusetts, with a branch in Cambridge, United Kingdom, Cerevance utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, within mature human brain tissue. By leveraging a substantial repository of over 15,000 human brain samples, the company generates extensive expression and epigenetic data, guiding the identification of promising therapeutic targets. This approach aims to address the early onset of central nervous system diseases by revealing critical transcriptional and epigenetic differences within affected brain regions.

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, that specializes in developing device-based therapies for neurodegenerative diseases. The company focuses on the delivery and monitoring of cerebrospinal fluid (CSF) and employs a proprietary therapeutic platform designed to remove toxic proteins from the CSF. EnClear's initial products are aimed at enhancing the quality of life for patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). Incorporated in 2018, EnClear Therapies is dedicated to advancing treatments that can halt disease progression and extend patient lives.

Atmosic Technologies, Inc., established in 2016 and headquartered in Campbell, California, is a fabless semiconductor company specializing in ultra-low power wireless technologies. Its core business is designing innovative solutions that significantly reduce or eliminate battery dependency in Internet of Things (IoT) devices. Atmosic's products, including the ATM2, ATM3, ATM33, and ATM34 series, enable IoT devices to harvest power from ambient energy sources like light, radio frequency, thermal, and kinetic energy. This technology benefits various IoT applications across personal, home, auto, healthcare, industrial, enterprise, and smart cities segments by minimizing maintenance costs and efforts associated with battery replacement.

GenomSys SA, established in 2016 and headquartered in Lausanne, Switzerland, specializes in developing tools and applications for processing and sharing DNA data. The company's core offering is a modular, robust, and certified platform that efficiently processes, stores, and shares genomic data. This platform, based on the ISO/IEC 23092 genomic standard, enables secure storage of individual DNA data on personal devices and facilitates sharing with practitioners for various applications, including diagnostics, pharmacogenomics, personalized treatments, and dietary recommendations. GenomSys' solutions are designed to be cheaper, faster, interoperable, and regulatory-conscious, accelerating the widespread adoption of personalized genomics.

Strateos specializes in automating chemistry, biology, and tissue analysis in closed-loop robotic labs, accelerating drug discovery programs for pharmaceutical partners. By combining advanced robotics, software for imaging and analytics, and remote cloud laboratories, Strateos enables more rapid and efficient discovery of new drug candidates. The company was formed through a merger of Transcriptic, which developed the first robotic cloud laboratory platform for life science research, and 3Scan, which specialized in automating tissue analysis. Strateos aims to express life science methods as data, enabling infrastructure virtualization and driving the next generation of discovery with significant time and cost efficiencies.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages groundbreaking research from the Akassoglou lab at Gladstone/UCSF, which identifies fibrin as a crucial factor in driving chronic innate immune activation associated with various diseases. By creating therapeutics that address neuroinflammation and vascular dysfunction, Therini Bio aims to provide potential treatments for conditions such as multiple sclerosis, thereby enhancing the quality of life for patients facing these challenging health issues.

Lightform, Inc. is a computer vision and hardware company based in San Francisco, California, founded in 2014. The company specializes in developing technology for projected augmented reality, offering sound-reactive projectors, projector kits, and creator products that transform spaces through projection mapping. Lightform's innovative hardware tools and desktop application enable users to create animated content for various scenes, control projectors wirelessly from laptops or phones, and seamlessly integrate real objects with projected light. The company also provides 3D scanning options that allow for the scanning of complex scenes, automatically fine-tuning alignment and enhancing the projection mapping workflow with AI-generated effects and filters.

NativeWaves is a technology company that specializes in audio synchronization and streaming solutions aimed at enhancing live event viewing experiences. By collaborating with partners, the company identifies compelling content and develops tools that allow for personalized and synchronized delivery of multimedia content across multiple screens. NativeWaves' software effectively translates movies, sports events, and videos into various languages without causing interruptions or synchronization delays. Additionally, it provides real-time statistics and insights on alternate screens, enabling viewers to engage with their favorite events in preferred languages and formats. The company's commitment to delivering intuitive and user-friendly technology ensures that existing workflows remain unchanged while enhancing the overall experience for audiences worldwide.

Kuprion Inc., established in 2016 and headquartered in Palo Alto, California, specializes in manufacturing and licensing nano copper inks and pastes. The company's flagship product, NSA-16, is a nano copper solder adhesive designed for assembly in printable and flexible electronics, cables, displays, touch screens, antennas, RFID tags, additive manufacturing, injection molding, and antimicrobial applications in healthcare. Kuprion serves diverse markets such as aerospace, automotive, printed electronics, consumer electronics, mining, oil and gas, manufacturing, and laser diodes. The company's revolutionary nanoCopper technology, originally researched at Lockheed Martin, offers superior electrical and thermal conductivity, enabling smaller, more powerful products. Since commercializing the technology in 2019, Kuprion has secured Fortune 100 customers, obtained over 20 patents, and established offices and manufacturing facilities in San Jose, California.

Phylagen Inc., established in 2014 and based in San Francisco, specializes in microbiome data analytics. The company employs DNA sequencing and machine learning to analyze environmental microbes, providing insights for diverse industries such as healthcare, agriculture, and manufacturing. Phylagen's core offering is an automated biosensor designed to map and understand microbial genetics indoors, enabling early pathogen detection (including COVID-19), allergen monitoring, and overall microbial health management for human well-being and safety.

Ultraleap Limited is a leading developer of mid-air haptic control systems and 3D hand tracking technology. Formerly known as Ultrahaptics, the company specializes in creating solutions that utilize ultrasound to generate tactile sensations, enabling users to feel three-dimensional shapes and textures without physical contact. Its flagship products include the Leap Motion Controller, which captures hand movements, and the VR Developer Mount, designed for enhancing virtual reality experiences on various headsets. The company's innovative technology is applicable across multiple industries such as extended reality, automotive, digital signage, industrial automation, consumer electronics, and location-based entertainment. Established in 2013 and headquartered in Bristol, United Kingdom, Ultraleap also has a subsidiary in Silicon Valley, United States.

Mojo Vision Inc. is a technology company based in Saratoga, California, founded in 2015. The company specializes in the development of augmented reality solutions, focusing on high-performance micro-LED display technology. Mojo Vision has created the world's smallest and densest dynamic display for smart contact lenses, which are designed to provide users with timely information seamlessly and hands-free, without the distractions associated with traditional mobile devices. The company is also engaged in a joint development agreement with Menicon Co., Ltd. to explore smart contact lens products, further enhancing its innovative offerings. By combining advanced display and semiconductor expertise with proprietary quantum-dot technology, Mojo Vision aims to revolutionize the display industry, addressing diverse applications across consumer, enterprise, and government sectors.

System1 Biosciences, Inc. is a San Francisco-based neurotherapeutics company established in 2017, specializing in drug discovery for complex neurological and psychiatric disorders, including epilepsy, autism, and schizophrenia. The company employs phenotypic screening, integrating cerebral organoid science, systems neuroscience, robotic automation, and advanced data analytics to uncover novel characterizations of diseases. This innovative approach allows System1 to identify "deep phenotypes," which are utilized to discover new therapeutic targets and drug treatments, addressing gaps in traditional discovery techniques that have struggled with these challenging conditions.

Vium, Inc. is a biotechnology company founded in 2013 and headquartered in San Mateo, California. It specializes in developing digital biomarkers aimed at enhancing preclinical research and animal welfare. The company is fully accredited by AAALAC International and has received significant commendation for its commitment to the principles of humane animal research. Vium's digital platform, known as Digital Vivarium and Vium Cloud, utilizes advanced technologies such as computer vision, artificial intelligence, and machine learning to non-invasively collect physiological metrics and behaviors. This innovative approach enables researchers and drug developers to gain improved insights into disease progression, thereby facilitating better decision-making regarding which compounds should progress to clinical trials. Its clientele includes a diverse array of biotechnology, pharmaceutical, and academic institutions, as well as novel therapeutic laboratories, all seeking more sensitive and accurate data for replicable studies.

Paradromics, Inc. is a company focused on developing advanced brain-machine interfaces aimed at transmitting data between the brain and external devices. Founded in 2015 and based in Austin, Texas, Paradromics manufactures implantable systems that facilitate neural data decoding, converting intricate neural recordings into data streams suitable for various neural prostheses. The company's technology is designed to enhance data transmission rates, providing high-volume, bidirectional data streaming capabilities. This innovation aims to assist individuals with neurodegenerative diseases and other neurological conditions by compensating for the loss of biological connectivity. In addition to its core products, Paradromics also develops applications to support its technology solutions.

Zebra Medical Vision Ltd. is a developer of an advanced imaging analytics platform that enhances the capabilities of healthcare institutions in diagnosing and managing diseases. Founded in 2014 and based in Shefayim, Israel, the company provides clinicians with tools for identifying patients at risk of various conditions and facilitates improved preventative treatment pathways. Its platform features advanced learning and computer vision diagnostic algorithms, catering to both healthcare providers and machine-learning researchers. Zebra Medical Vision has established strategic collaborations with organizations such as USARAD Holdings and TELUS Ventures, and its products have received FDA clearance for use in hospitals worldwide, including locations in Australia, India, Europe, the U.S., and Latin America. The company is recognized for its role in the AI and machine learning landscape, having raised significant funding to support its innovative solutions in medical imaging.

Quince Therapeutics is a preclinical stage biopharmaceutical company dedicated to developing innovative precision therapeutics for debilitating and rare diseases. The company has created a unique bone-targeting drug platform that enables the precise delivery of small molecules, peptides, or large molecules directly to the site of bone fractures and diseases. This targeted approach aims to enhance healing rates while minimizing off-target safety concerns often associated with non-targeted therapies. Quince Therapeutics focuses on addressing impairments related to strength, functionality, debilitating pain, and other serious health challenges.

Phase Four LLC, founded in 2015 and based in Pasadena, California, specializes in the manufacture of satellite propulsion systems, particularly for small satellites. The company is known for its innovative Radio Frequency Thruster (RFT), which distinguishes itself by omitting traditional components such as hollow cathodes and high voltage electronics. This design leads to substantial benefits, including a tenfold reduction in materials costs compared to legacy electric propulsion systems, a significant decrease in the size of power electronics, and versatility in propellant use. Phase Four's propulsion solutions are utilized in various space missions, including commercial, civil, and scientific endeavors, and are engineered to optimize performance while maintaining a competitive thrust-to-power ratio. The company also offers products like the CubeSats ambipolar thruster and the Maxwell plasma propulsion solution, contributing to the efficient maneuvering of satellites across diverse orbital trajectories.

Atomwise, Inc. is a biotechnology company specializing in deep learning artificial intelligence technology for small molecule drug discovery. Based in San Francisco and founded in 2012, the company has developed AtomNet, a pioneering AI platform that facilitates virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical analysis of experimental affinity measurements and protein structures. Atomwise is focused on addressing over 600 unique disease targets and has established collaborations with over 250 partners, including prominent pharmaceutical and biotechnology firms. By leveraging its advanced technology, Atomwise aims to revolutionize the drug discovery process and advance a pipeline of small-molecule drug candidates into preclinical studies. The company was previously known as Chematria, Inc. and rebranded to Atomwise, Inc. in 2015.

Envisagenics, Inc. is a bioinformatics company founded in 2013 and headquartered in Huntington, New York. The company specializes in RNA therapeutics and aims to simplify complex biomedical data to expedite the development of innovative therapeutic solutions. Envisagenics leverages its advanced analytics platform, SpliceCore, which utilizes artificial intelligence and machine learning to analyze RNA sequencing data. This cloud-based platform enables researchers to identify splicing errors linked to various diseases, including genetic disorders and cancers, and to discover potential drug targets and biomarkers. By streamlining the drug discovery process through computational simulations, Envisagenics significantly reduces the time, cost, and risks associated with drug development, thereby facilitating partnerships with biopharmaceutical companies to advance RNA-based therapies.

Ursa Major Technologies, Inc., established in 2015 and based in Berthoud, Colorado, specializes in manufacturing propulsion solutions tailored for the microsatellite and nanosatellite launch market. The company's product portfolio includes the Ursa Major Hadley and Ripley engines, which are predominantly (over 80%) additively manufactured using innovative, proprietary materials and processes. These engines, running on liquid oxygen and kerosene, are designed to provide superior performance, reliability, and cost-effectiveness for aerospace clients.

Lightform, Inc. is a computer vision and hardware company based in San Francisco, California, founded in 2014. The company specializes in developing technology for projected augmented reality, offering sound-reactive projectors, projector kits, and creator products that transform spaces through projection mapping. Lightform's innovative hardware tools and desktop application enable users to create animated content for various scenes, control projectors wirelessly from laptops or phones, and seamlessly integrate real objects with projected light. The company also provides 3D scanning options that allow for the scanning of complex scenes, automatically fine-tuning alignment and enhancing the projection mapping workflow with AI-generated effects and filters.

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing small molecules aimed at restoring neuronal health and halting neurodegeneration. The company's lead product candidate, ATH-1017, is a small molecule designed to penetrate the blood-brain barrier and acts as a hepatocyte growth factor/MET activator, currently undergoing various clinical trials for treating Alzheimer’s and Parkinson’s diseases. In addition to ATH-1017, Athira is developing several other candidates, including ATH-1019 for depression and ATH-1018 for peripheral neuropathy, which are in the preclinical stage. Founded in 2011 and initially known as M3 Biotechnology, Athira Pharma changed its name in April 2019 to reflect its mission of advancing innovative therapies to improve the lives of individuals affected by brain disorders.

Stellar Labs, Inc., incorporated in 2014 and based in Burlingame, California, operates within the technology sector, focusing on the private aviation industry. The company has developed an advanced commercial operations system that integrates an all-digital distribution network, aiming to transform and enhance business aviation. Stellar Labs offers a suite of cloud-based applications designed to cater to a range of operational needs, from simple single-aircraft management to complex operations involving large fleets and multiple bases. This innovative approach positions Stellar Labs as a key player in revolutionizing the efficiency and effectiveness of private aviation services.

Chirp Microsystems, Inc. is a company specializing in the design, development, and manufacturing of low power ultrasonic three-dimensional sensing solutions. Founded in 2013 and headquartered in Berkeley, California, the company focuses on applications in consumer electronics, smart homes, and industrial automation. Chirp's systems deliver millimeter-accurate range information, utilizing machine learning and neural network algorithms to outperform traditional infrared-based alternatives in various real-world scenarios. Their innovative technology enables always-on sensing capabilities for smart home devices, even when operating on battery power, thus enhancing functionality and user experience across their target markets.

Mixed Dimensions Inc. is a software development company based in San Francisco, California, that specializes in the three-dimensional (3D) printing industry. Founded in 2009, the company offers several innovative solutions, including Makeprintable, a cloud-based service that optimizes 3D CAD files by fixing errors to ensure they are suitable for printing. It also provides 3D Collectible, which integrates a printing technology platform with existing 3D printers to produce customizable printed objects. Additionally, Mixed Dimensions has developed Gameprint, a platform designed to capture and share gameplay moments in a 3D environment. The company's focus on bridging the digital and physical worlds enhances user experiences in game development and 3D printing, allowing for the on-demand creation of unique, one-of-a-kind products.

Alzeca Biosciences, founded in 2011 and headquartered in Houston, Texas, specializes in developing novel magnetic resonance imaging (MRI) contrast agents for early diagnosis of neurodegenerative diseases like Alzheimer's. Its flagship product, ADx nanoparticle, targets amyloid plaques, currently undergoing Phase 1 human clinical trials. The company aims to address the growing global prevalence and economic burden of Alzheimer's disease, which affects millions worldwide and is projected to quadruple by 2050 without more effective diagnostic methods.

Tempo Automation Holdings, established in 2013 and headquartered in San Francisco, specializes in manufacturing low-volume electronics products. The company's core business involves designing and assembling printed circuit boards (PCBs) using a unique, software-automated platform. This platform enables Tempo to provide unparalleled speed, quality, and transparency, particularly during the critical prototype and new product introduction stages. Serving leading innovators across industries such as aerospace, medical technology, and automotive, Tempo Automation empowers its customers to accelerate product development and time to market.

Ultraleap Limited is a leading developer of mid-air haptic control systems and 3D hand tracking technology. Formerly known as Ultrahaptics, the company specializes in creating solutions that utilize ultrasound to generate tactile sensations, enabling users to feel three-dimensional shapes and textures without physical contact. Its flagship products include the Leap Motion Controller, which captures hand movements, and the VR Developer Mount, designed for enhancing virtual reality experiences on various headsets. The company's innovative technology is applicable across multiple industries such as extended reality, automotive, digital signage, industrial automation, consumer electronics, and location-based entertainment. Established in 2013 and headquartered in Bristol, United Kingdom, Ultraleap also has a subsidiary in Silicon Valley, United States.

Quince Therapeutics is a preclinical stage biopharmaceutical company dedicated to developing innovative precision therapeutics for debilitating and rare diseases. The company has created a unique bone-targeting drug platform that enables the precise delivery of small molecules, peptides, or large molecules directly to the site of bone fractures and diseases. This targeted approach aims to enhance healing rates while minimizing off-target safety concerns often associated with non-targeted therapies. Quince Therapeutics focuses on addressing impairments related to strength, functionality, debilitating pain, and other serious health challenges.

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing small molecules aimed at restoring neuronal health and halting neurodegeneration. The company's lead product candidate, ATH-1017, is a small molecule designed to penetrate the blood-brain barrier and acts as a hepatocyte growth factor/MET activator, currently undergoing various clinical trials for treating Alzheimer’s and Parkinson’s diseases. In addition to ATH-1017, Athira is developing several other candidates, including ATH-1019 for depression and ATH-1018 for peripheral neuropathy, which are in the preclinical stage. Founded in 2011 and initially known as M3 Biotechnology, Athira Pharma changed its name in April 2019 to reflect its mission of advancing innovative therapies to improve the lives of individuals affected by brain disorders.

Echo is a provider of am automated microscope intended for biological research and pathologies. The company's product provides features like inverted images, cell counting, phase contrast, brightfield and fluorescence, enabling customers to have accurate images at a lower cost.

DigiLens Inc. is a technology company based in Sunnyvale, California, specializing in holographic waveguide display solutions for extended reality (XR) applications. Founded in 1997 and formerly known as SBG Labs, DigiLens has developed a patented optical platform and photopolymer technology that enables original equipment manufacturers (OEMs) to create customizable XR devices for various sectors, including automotive, enterprise, consumer, avionics, and military. The company offers a range of products, such as the Crystal30 and Crystal50 lenses, which facilitate the design of waveguide-based displays. Additionally, DigiLens provides innovative solutions like the DigiLens AutoHUD, which enhances the field of view of traditional heads-up displays, and CrystalClear, an augmented reality heads-up display. Supporting its offerings, DigiLens also supplies light engines and hardware development kits, such as Insight30, to assist users in developing wearable devices.

Tetra Therapeutics Inc. is a clinical-stage biotechnology company focused on developing pharmaceutical drugs that target phosphodiesterase (PDE) subtype inhibitors for various neurological and non-neurological disorders. The company is advancing BPN14770, a novel therapeutic agent designed to enhance synaptic actions in the brain's neurons, which is particularly relevant for conditions affecting memory and cognition, such as Alzheimer's disease, schizophrenia, and developmental disabilities. Tetra Therapeutics aims to create effective treatments for patients suffering from Alzheimer's, other dementias, traumatic brain injury, and psychiatric disorders. Founded in 2011 and based in Grand Rapids, Michigan, the company was previously known as Tetra Discovery Partners and rebranded in August 2019. Tetra Therapeutics has established a strategic collaboration with Shionogi & Co., Ltd., and as of July 2020, operates as a subsidiary of Shionogi.

Podium Data, Inc. is a data management software company based in Lowell, Massachusetts, founded in 2014. It specializes in providing an enterprise data management platform that transforms traditional data supply chains into a self-service, on-demand marketplace. This platform allows businesses to efficiently manage, prepare, and deliver analytics-ready data to users across various data landscapes. Podium Data's solutions include capabilities for source parsing, data profiling, metadata management, data integration, and data transformation, among others. By leveraging big data technologies, the company aims to accelerate the time-to-answer for businesses, enabling them to quickly find, understand, and utilize any enterprise data source, regardless of its physical location. As of 2018, Podium Data operates as a subsidiary of Qlik Technologies, Inc.

3Scan, Inc. is a technology company based in San Francisco, California, that specializes in the development of advanced microscopy tools and software for tissue analysis. Founded in 2011, the company focuses on automating the processes of tissue sectioning and imaging through its innovative knife-edge scanning microscopes. By integrating automation, machine learning, and computer vision, 3Scan enables researchers and medical professionals to extract spatial data from tissue samples, facilitating detailed 3D visualizations and comprehensive quantitative analysis of complex anatomical structures. This approach enhances the throughput and accuracy of tissue analysis compared to traditional histopathology, ultimately advancing the understanding of diseases that manifest at the tissue level, such as cancer, Alzheimer's, and other neurodegenerative disorders. 3Scan's technology aims to drive the discovery of new diagnostics and therapeutics in the field of biomedical research.

Zebra Medical Vision Ltd. is a developer of an advanced imaging analytics platform that enhances the capabilities of healthcare institutions in diagnosing and managing diseases. Founded in 2014 and based in Shefayim, Israel, the company provides clinicians with tools for identifying patients at risk of various conditions and facilitates improved preventative treatment pathways. Its platform features advanced learning and computer vision diagnostic algorithms, catering to both healthcare providers and machine-learning researchers. Zebra Medical Vision has established strategic collaborations with organizations such as USARAD Holdings and TELUS Ventures, and its products have received FDA clearance for use in hospitals worldwide, including locations in Australia, India, Europe, the U.S., and Latin America. The company is recognized for its role in the AI and machine learning landscape, having raised significant funding to support its innovative solutions in medical imaging.

Yumanity Therapeutics is a biotechnology company dedicated to transforming drug discovery for neurodegenerative diseases linked to protein misfolding. Founded in December 2014 by protein folding expert Susan Lindquist and biotech leader Tony Coles, Yumanity aims to develop innovative, disease-modifying therapies to address critical unmet medical needs in conditions such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company leverages proprietary platforms to identify potential therapeutic targets and has made progress in advancing a new chemical lead series specifically for Parkinson’s disease, while also exploring additional compounds for Alzheimer's disease and ALS.

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing small molecules aimed at restoring neuronal health and halting neurodegeneration. The company's lead product candidate, ATH-1017, is a small molecule designed to penetrate the blood-brain barrier and acts as a hepatocyte growth factor/MET activator, currently undergoing various clinical trials for treating Alzheimer’s and Parkinson’s diseases. In addition to ATH-1017, Athira is developing several other candidates, including ATH-1019 for depression and ATH-1018 for peripheral neuropathy, which are in the preclinical stage. Founded in 2011 and initially known as M3 Biotechnology, Athira Pharma changed its name in April 2019 to reflect its mission of advancing innovative therapies to improve the lives of individuals affected by brain disorders.

Modsy is a home design company that leverages advanced 3D graphics and computer vision technology to offer personalized interior design solutions. Founded in 2015 and based in San Francisco, the company enables customers, including new homeowners, remodelers, and renters, to visualize inspirational designs and decor within their own spaces before making any changes. Modsy's software allows users to see how furniture and decor will look in their homes, providing tailored room layouts and recommendations. It also features a shoppable marketplace, allowing customers to purchase items directly from their design plans, thereby simplifying the home design process and eliminating guesswork for both home renovators and interior designers.

Quince Therapeutics is a preclinical stage biopharmaceutical company dedicated to developing innovative precision therapeutics for debilitating and rare diseases. The company has created a unique bone-targeting drug platform that enables the precise delivery of small molecules, peptides, or large molecules directly to the site of bone fractures and diseases. This targeted approach aims to enhance healing rates while minimizing off-target safety concerns often associated with non-targeted therapies. Quince Therapeutics focuses on addressing impairments related to strength, functionality, debilitating pain, and other serious health challenges.

Eargo, Inc. is a consumer-focused medical device company specializing in the design and sale of hearing aids for individuals with hearing loss in the United States. Founded in 2010 and headquartered in San Jose, California, Eargo offers innovative, rechargeable hearing aids that can be controlled via smartphone, enhancing user convenience. The company provides online hearing screenings and virtual support, eliminating the need for in-person consultations. By adopting a direct-to-consumer model, Eargo aims to make hearing aids more accessible and reduce the social stigma often associated with them. Its user-centric approach addresses the common challenges of traditional hearing aid adoption, including cost and accessibility, thereby improving the quality of life for those with hearing difficulties.

PharmatrophiX, Inc. is a biopharmaceutical company based in Menlo Park, California, specializing in the development of disease-modifying small molecule drugs for neurodegenerative disorders. Founded in 2005 by Stanford researcher Frank Longo, the company focuses on creating drugs that mimic the activity of neurotrophins, proteins crucial for the health and survival of neurons. PharmatrophiX utilizes its proprietary technology to develop small molecules that modulate neurotrophin receptor signaling, particularly targeting the p75 receptor and Trk ligand programs. One of its notable compounds, a modified version of LM11A-31, can penetrate the blood-brain barrier, making it essential for treating brain disorders. The company's innovations aim to decrease synaptic and neuronal degeneration, offering potential treatments for conditions such as Alzheimer's disease.